UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 161

Sortiert nach

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Inflammatory bowel diseases, 2012-01, Vol.18 (1), p.1-9

2012

Link zum Volltext

Verfügbarkeit prüfen

Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2020-07, Vol.52 (1), p.73-84

2020

Link zum Volltext

Verfügbarkeit prüfen

Stopping Biologics in IBD-What Is the Evidence?

Inflammatory bowel diseases, 2018-03, Vol.24 (4), p.725-731

Louis, Edouard

2018

Link zum Volltext

Verfügbarkeit prüfen

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Inflammatory bowel diseases, 2007-02, Vol.13 (2), p.135-142

2007

Link zum Volltext

Verfügbarkeit prüfen

Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

The American journal of gastroenterology, 2012-12, Vol.107 (12), p.1770-1776

2012

Link zum Volltext

Verfügbarkeit prüfen

Long-term summer (AD751-2008) temperature fluctuation in the French Alps based on tree-ring data

Boreas, 2011-04, Vol.40 (2), p.351-366

2011

Link zum Volltext

Verfügbarkeit prüfen

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

The American journal of gastroenterology, 2002-09, Vol.97 (9), p.2357-2363

2002

Link zum Volltext

Verfügbarkeit prüfen

Immunosuppressant combined with infliximab in Crohn's Disease: For 6 months, for 2 years, or forever?

Inflammatory bowel diseases, 2011-03, Vol.17 (3), p.858-859

Louis, Edouard

2011

Link zum Volltext

Verfügbarkeit prüfen

S734 IBD Patients’ Treatment Preferences Are Heterogeneous, but Largely Affected by the Avoidance of Abdominal Pain and Side Effects (P-POWER IBD Study)

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S337-S337

2021

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence

United European gastroenterology journal, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Inflammatory bowel diseases, 2019-01, Vol.25 (1), p.156-162

2019

Link zum Volltext

Verfügbarkeit prüfen

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

Inflammatory bowel diseases, 2014-06, Vol.20 (6), p.978-986

2014

Link zum Volltext

Verfügbarkeit prüfen

S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S322-S323

2020

Link zum Volltext

Verfügbarkeit prüfen

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Inflammatory bowel diseases, 2024-02, Vol.30 (2), p.240-246

2024

Link zum Volltext

Verfügbarkeit prüfen

S943 Analysis of International Spontaneous Reporting System Databases for Safety of Corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and Consequences of Corticosteroid Excess (DICE)-Impact Study

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S448-S449

2021

Link zum Volltext

Verfügbarkeit prüfen

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Inflammatory bowel diseases, 2017-03, Vol.23 (3), p.333-340

2017

Link zum Volltext

Verfügbarkeit prüfen

The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

The American journal of gastroenterology, 2022, Vol.117 (10 Suppl.), p.S704

2022

Link zum Volltext

Verfügbarkeit prüfen

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Inflammatory bowel diseases, 2013-05, Vol.19 (6), p.1112-1122

2013

Link zum Volltext

Verfügbarkeit prüfen

Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology

Alimentary pharmacology & therapeutics, 2021-09, Vol.54 (6), p.779-791

2021

Link zum Volltext

Verfügbarkeit prüfen

Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies

Alimentary pharmacology & therapeutics, 2019-12, Vol.50 (11-12), p.1204-1213

2019

Link zum Volltext

Verfügbarkeit prüfen

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

The American journal of gastroenterology, 2022-12, Vol.117 (12S), p.S10-S10

2022

Link zum Volltext

Verfügbarkeit prüfen

S713 Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients With Moderate to Severe Crohn’s Disease

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e496-e497

2022

Link zum Volltext

Verfügbarkeit prüfen

S822 Fatigue Improvement Correlates With Reductions in Work Productivity Impairment and Related Indirect Cost in Patients With Crohn’s Disease: Post Hoc Analysis of Phase 3 Rizankizumab Induction Trials

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e591-e592

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 161

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Journals Frontfile Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(115)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Wiley Online Library
(161)
Journals@Ovid Full Text
(143)
IngentaConnect Journals
(81)
MEDLINE
(73)
Wiley Online Library
(66)
IngentaConnect Journals
(62)
Open access e-journals
(53)
NUS Single-Journal Subscriptions
(52)
Nature
(46)
Oxford journals
(42)
Oxford Journals 2020 Medicine
(36)
SAGE Journals
(5)
JSTOR
(4)
Springer journals
(2)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1)
Elsevier ScienceDirect Journals Complete
(1)

11 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

Stopping Biologics in IBD-What Is the Evidence?

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

Long-term summer (AD751-2008) temperature fluctuation in the French Alps based on tree-ring data

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

Immunosuppressant combined with infliximab in Crohn's Disease: For 6 months, for 2 years, or forever?

S734 IBD Patients’ Treatment Preferences Are Heterogeneous, but Largely Affected by the Avoidance of Abdominal Pain and Side Effects (P-POWER IBD Study)

Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

S943 Analysis of International Spontaneous Reporting System Databases for Safety of Corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and Consequences of Corticosteroid Excess (DICE)-Impact Study

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology

Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

S713 Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients With Moderate to Severe Crohn’s Disease

S822 Fatigue Improvement Correlates With Reductions in Work Productivity Impairment and Related Indirect Cost in Patients With Crohn’s Disease: Post Hoc Analysis of Phase 3 Rizankizumab Induction Trials

Development of the Crohn's disease digestive damage score, the Lémann score

Aktive Filter

Suchergebnisse filtern